acyl-CoA synthetase bubblegum family member 1Genealiases: BG · BG1 · BGM · GR-LACS · LPD
Q-omics provides the consensus-scored ACSBG1 profile across patient tissues and cancer cell-line models. ACSBG1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ACSBG1 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, ACSBG1 RNA expression shows 17,391 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where ACSBG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSBG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSBG1 survival associations across molecular data types. ACSBG1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSBG1 RNA expression–survival associations across cancer types. High ACSBG1 expression shows unfavorable associations in UVM, COAD and THCA, but favorable associations in CESC, ACC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ACSBG1 RNA expression.
This table summarizes ACSBG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ACSBG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSBG1 shows lower tumor expression in LUAD, COAD, LUSC and STAD and higher tumor expression in KICH and CHOL. The LUAD box plot shows higher ACSBG1 RNA expression in normal versus tumor tissue (log2 FC = −0.415, t-test p < 0.001).
This table shows molecular features associated with ACSBG1 in patient tissues and cancer cell lines. In patient samples, ACSBG1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSBG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
